within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE30_NirmatrelvirAndRitonavir;

model NirmatrelvirAndRitonavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AE30;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AE30</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nirmatrelvir and ritonavir is a combination antiviral therapy used primarily in the treatment of COVID-19. Nirmatrelvir is a SARS-CoV-2 3CL protease inhibitor, while ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism, thereby increasing plasma concentrations of nirmatrelvir. This combination (marketed as Paxlovid) is approved for emergency use and treatment of COVID-19 in many countries.</p><h4>Pharmacokinetics</h4><p>Representative pharmacokinetic parameters for nirmatrelvir/ritonavir in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Saravolatz, LD, et al., &amp; Sharma, M (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 76(1) 165–171. DOI:<a href=\"https://doi.org/10.1093/cid/ciac180\">10.1093/cid/ciac180</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35245942/\">https://pubmed.ncbi.nlm.nih.gov/35245942</a></p></li><li><p>Hammond, J, et al., &amp; Rusnak, JM (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. <i>The New England journal of medicine</i> 386(15) 1397–1408. DOI:<a href=\"https://doi.org/10.1056/NEJMoa2118542\">10.1056/NEJMoa2118542</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35172054/\">https://pubmed.ncbi.nlm.nih.gov/35172054</a></p></li><li><p>Cox, DS, et al., &amp; Damle, B (2023). Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults. <i>British journal of clinical pharmacology</i> 89(9) 2867–2876. DOI:<a href=\"https://doi.org/10.1111/bcp.15788\">10.1111/bcp.15788</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37184075/\">https://pubmed.ncbi.nlm.nih.gov/37184075</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end NirmatrelvirAndRitonavir;
